減肥藥是否也有助於改善心理健康？
Could Weight-Loss Drugs Also Help Mental Health?
近期發表於《刺胳針精神醫學》(ㄘˋㄍㄜˊㄓㄣˋㄐㄧㄥㄧㄕㄣˊㄧˋㄒㄩㄝˊ)期刊的研究，引發了各界對於類升糖素胜肽-1受體致效劑（如司美格魯肽）是否能提供體重管理之外益處的興趣。
Recent research published in The Lancet Psychiatry has sparked interest in whether GLP-1 receptor agonists, such as semaglutide, could offer benefits beyond weight management.
研究顯示，這些藥物與既有焦慮或憂鬱症患者的療效改善之間可能存在關聯。
Studies show a potential link between these drugs and improved outcomes for patients with pre-existing anxiety or depression.
具體而言，司美格魯肽的使用者其心理健康症狀惡化的風險降低了42%。
Specifically, users of semaglutide saw a 42% lower risk of their mental health symptoms worsening.
直接上，這些藥物或許能調節大腦獎勵系統中的多巴胺，並具備保護神經元的抗發炎特性。
Directly, the drugs might modulate dopamine in the brain’s reward system and possess anti-inflammatory properties that protect neurons.
目前的證據大多仍屬於觀察性，意味著仍需完整的臨床試驗來證實其對精神疾病的直接治療效果。
Much of the evidence remains observational, meaning full clinical trials are still required to confirm a direct therapeutic effect for psychiatric conditions.
雖然研究人員持續監控安全性並探索其對阿茲海默症等疾病的潛在神經保護益處，但他們強調，這些藥物應被視為輔助工具，而非取代專業心理健康照護的替代方案。
While researchers continue to monitor safety and explore potential neuroprotective benefits for conditions like Alzheimer’s, they emphasize that these medications should be viewed as supportive tools rather than a substitute for dedicated mental health care.
